Related by context. All words. (Click for frequent words.) 72 BAY #-# 70 vandetanib 70 pertuzumab 69 INCB# [001] 68 axitinib 68 HGS ETR1 68 PXD# 68 MGd 67 phase IIb clinical 67 INCB# [002] 67 XL# [003] 67 Amrubicin 67 Phase 2b trial 67 Phase 2b study 67 elotuzumab 67 HuMax CD4 67 sunitinib malate 67 forodesine 67 ganetespib 67 phase Ib 67 panitumumab 67 neratinib 66 Phase 2a trial 66 Amigal 66 sorafenib Nexavar 66 lintuzumab 66 tanespimycin 66 BRIM2 66 XmAb# 66 decitabine 66 JAK inhibitor 66 TYKERB 66 Plicera 66 HGS# 66 glufosfamide 66 sorafenib tablets 66 alvespimycin 66 vorinostat 66 docetaxel chemotherapy 66 carfilzomib 66 Panzem R NCD 66 placebo controlled Phase 66 Phase Ib 66 Traficet EN 66 OXi# 66 CA4P 65 ixabepilone 65 YONDELIS 65 HuMax EGFr 65 IMC A# 65 enzastaurin 65 PF # [001] 65 TELCYTA 65 CIMZIA TM 65 bevacizumab Avastin 65 eltrombopag 65 HGS ETR2 65 multicenter Phase 65 mTOR inhibitor 65 PS# [001] 65 TG# [003] 65 dacetuzumab 65 Phase 1b 65 ELACYT 65 evaluating tivozanib 65 Vectibix 65 MAGE A3 ASCI 65 oral prodrug 65 TORISEL 65 HuMax CD# 65 AVASTIN 65 otelixizumab 65 temsirolimus 65 Targretin 65 Phase 1b trial 65 perifosine 65 cediranib 65 Phase 2b clinical 65 Xanafide 65 thymalfasin 65 MGCD# [001] 65 mapatumumab 64 gefitinib Iressa 64 GAMMAGARD 64 cilengitide 64 AEG# 64 posaconazole 64 Tasimelteon 64 MDV# 64 Phase Ib clinical 64 Chemophase 64 ACTEMRA TM 64 Catena ® 64 sunitinib 64 nitazoxanide 64 teriflunomide 64 pharmacokinetic PK 64 cetuximab Erbitux ® 64 Imprime PGG 64 iniparib 64 Fludara 64 FOLOTYN 64 Aflibercept 64 Nexavar ® 64 registrational trial 64 metastatic HRPC 64 ZOLINZA 64 nab paclitaxel 64 dexpramipexole 64 phase IIa clinical 64 alvimopan 64 Torisel 64 docetaxel Taxotere ® 64 daclizumab 64 Laquinimod 64 angiogenesis inhibitor 64 Phenoptin 64 Tamibarotene 64 LY# [003] 64 APTIVUS r 64 eniluracil 64 temozolomide 64 FOLFIRI 64 DAVANAT 64 Dapagliflozin 64 mertansine 64 Vilazodone 64 azacitidine 64 erlotinib Tarceva ® 64 APTIVUS 64 Ceflatonin 64 PegIntron 64 Bortezomib 64 low dose cytarabine 64 dose escalation trial 64 aflibercept 64 gemcitabine 64 sapacitabine 64 bosentan 64 sorafenib Nexavar ® 64 virus HCV protease inhibitor 64 Mipomersen 64 CR# vcMMAE 64 albinterferon alfa 2b 64 ELND# 64 PROMACTA 64 Bevacizumab 64 Combidex 64 monotherapy 64 ProSavin 64 Tyrima 64 sorafenib 64 RAD# [003] 64 Tarceva erlotinib 64 receptor tyrosine kinase inhibitor 64 vemurafenib 64 cell lymphoma CTCL 64 bosutinib 64 ACTEMRA 64 Phase 2a 64 active comparator 64 EFAPROXYN 64 selective modulator 64 interferon alfa 64 HER2 positive metastatic breast 63 dacarbazine 63 alfa 2a 63 KRN# 63 Azedra 63 PEG Interferon lambda 63 BRIM3 63 ISENTRESS 63 sitaxsentan 63 Phase IIb trials 63 pralatrexate 63 HuLuc# 63 ritonavir boosted 63 Debio 63 Pegasys ® 63 pomalidomide 63 investigational compound 63 Azixa 63 Tarceva TM 63 R#/MEM # 63 ASA# 63 dyskinesia PD LID 63 Factor VIIa 63 PD LID 63 trabectedin 63 Phase IIB 63 Ambrisentan 63 rNAPc2 63 Dacogen injection 63 Gemzar ® 63 zalutumumab 63 bendamustine 63 Pralatrexate 63 visilizumab 63 APPRAISE 63 ISIS # 63 VELCADE melphalan 63 OncoVEX GM CSF 63 FOLFOX6 chemotherapy regimen 63 refractory chronic lymphocytic 63 histone deacetylase HDAC inhibitor 63 Phase 2a clinical 63 Insegia 63 MabCampath 63 belinostat 63 AGILECT R 63 Copegus ribavirin 63 galiximab 63 apremilast 63 PDE4 inhibitor 63 TMC# C# 63 Avastin bevacizumab 63 adalimumab 63 cetuximab Erbitux 63 Aplidin 63 Amplimexon 63 Taxotere ® 63 phase IIb 63 EOquin TM 63 GSK# [001] 63 Perifosine 63 GALNS 63 ADVEXIN 63 FOLFOX6 63 Phase Ib II 63 rFIXFc 63 phase IIa 63 vismodegib 63 panitumumab Vectibix 63 PRT# 63 ruxolitinib 63 metaglidasen 63 cutaneous T cell 63 PRX # 63 cetuximab Erbitux R 63 imetelstat 63 romidepsin 63 celgosivir 63 GRN#L 63 FOLOTYN ® 63 docetaxel Taxotere R 63 pegylated interferon alfa 2a 63 relapsing multiple sclerosis 63 Randomized Phase 63 RDEA# 63 Genasense 63 lapatinib Tykerb 63 safinamide 63 Xcytrin 62 ocrelizumab 62 brivaracetam 62 oral ridaforolimus 62 nilotinib 62 fosbretabulin 62 PEG SN# 62 AEGR 62 gemcitabine chemotherapy 62 carboplatin paclitaxel 62 investigational humanized monoclonal antibody 62 Cloretazine 62 ofatumumab 62 TACI Ig 62 valopicitabine 62 clofarabine 62 relapsed refractory multiple myeloma 62 Trastuzumab 62 dose cohorts 62 Pimavanserin 62 atacicept 62 proteasome inhibitor bortezomib 62 Neulasta ® 62 anticancer agent 62 methylnaltrexone 62 huC# DM4 62 GW# [003] 62 metastatic renal cell carcinoma 62 RoACTEMRA 62 HCV protease inhibitor 62 Phase Ib study 62 peg IFN 62 placebo controlled Phase III 62 custirsen 62 Dasatinib 62 PEGASYS ® 62 generation purine nucleoside 62 SCH # 62 vicriviroc 62 LAF# 62 BCX# 62 dose escalation study 62 rindopepimut 62 MYDICAR ® 62 plus prednisone 62 adecatumumab 62 SNT MC# 62 relapsed multiple myeloma 62 tezampanel 62 Bezielle 62 PREZISTA r 62 mRCC 62 SUTENT 62 TELINTRA 62 dirucotide 62 Asentar 62 dimebon 62 AP# [003] 62 FTY# 62 gemcitabine Gemzar 62 JAK2 inhibitor 62 BRAF inhibitor 62 TYZEKA 62 TREANDA 62 metastatic hormone refractory 62 BENLYSTA ® 62 HQK 62 obatoclax 62 standard chemotherapy regimen 62 Phase IIa trial 62 entinostat 62 peginesatide 62 muraglitazar 62 AZILECT R 62 placebo controlled clinical 62 amrubicin 62 erlotinib 62 rilonacept 62 riociguat 62 EOquin 62 RSD# 62 NGX# 62 blinatumomab 62 VEGF Trap 62 ULORIC 62 teduglutide 62 Sym# 62 vinorelbine 62 Zevalin R Ibritumomab 62 phase IIb trial 62 taxane chemotherapy 62 Allovectin 7 R 62 Vandetanib 62 Pegasys R 62 CANCIDAS 62 castration resistant prostate cancer 62 CDK inhibitor 62 pegylated liposomal doxorubicin 62 glatiramer acetate 62 SRT# [003] 62 PEGINTRON TM 62 mg dose 62 Vidaza 62 irbesartan 62 pharmacodynamic PD 62 Phase 1b clinical 62 CIMZIA ™ 62 mipomersen 62 sargramostim 62 Phase Ib clinical trials 62 polymerase inhibitor 62 raltegravir 62 lymphoma CTCL 62 ruboxistaurin 62 novel VDA molecule 62 bortezomib Velcade R 62 R sorafenib tablets 62 seliciclib 62 VAPRISOL 62 Everolimus 62 OPAXIO 62 Proxinium TM 62 Apoptone 62 pharmacodynamic properties 62 Serdaxin 62 trastuzumab DM1 T DM1 62 IMA# 62 Golimumab 62 ranolazine 62 pharmacokinetic PK study 62 T DM1 62 DDP# 62 VIDAZA 62 ponatinib 62 docetaxel 62 Advexin 62 tyrosine kinase inhibitor 62 vidofludimus 61 Peginterferon 61 EP #R 61 BARACLUDE R 61 Ceplene/IL-2 61 ridaforolimus 61 Ixempra 61 ZD# [001] 61 telbivudine 61 YERVOY 61 canakinumab 61 Tanespimycin 61 RSD# iv 61 Phase IIa clinical 61 MEK inhibitor 61 gadobutrol 61 Zolinza 61 motesanib 61 ongoing Phase 1b 61 inhibitor RG# 61 bevacizumab Avastin ® 61 regadenoson 61 bazedoxifene 61 Tarceva 61 baminercept 61 fenofibric acid 61 HCD# [002] 61 Zerenex 61 SAR# [004] 61 immunomodulatory therapy 61 AIR CF1 61 ambrisentan 61 FOLFOX4 61 Revlimid lenalidomide 61 multicenter Phase II 61 dacarbazine DTIC 61 depsipeptide 61 infusional 5-FU/LV 61 Fibrillex TM 61 romiplostim 61 Phase #b/#a 61 Leukine 61 TLK# 61 tolerability profiles 61 plus dexamethasone 61 luteinizing hormone releasing 61 urocortin 2 61 registrational 61 AVONEX ® 61 interferon gamma 1b 61 Cloretazine R VNP#M 61 uric acid lowering 61 AZD# 61 Nexavar sorafenib 61 Blinatumomab 61 Panzem R 61 DU #b 61 MetMAb 61 Degarelix 61 PEGylated Fab fragment 61 Genasense ® 61 IL# PE#QQR 61 Sandostatin LAR 61 PSN# [002] 61 Velcade bortezomib 61 R#/MEM 61 perampanel 61 dose dose escalation 61 Rituxan rituximab 61 crizotinib PF # 61 ZACTIMA 61 tremelimumab 61 CYT# 61 Archexin 61 Azacitidine 61 pharmacodynamic 61 Ocrelizumab 61 recurrent glioblastoma multiforme 61 FASLODEX 61 initiate Phase 1b 61 Phase IIb trial 61 Clolar ® 61 humanized anti 61 VELCADE 61 LymphoStat B 61 Quinamed 61 favorable pharmacokinetic profile 61 tocilizumab 61 gefitinib 61 ZYBRESTAT 61 COPAXONE ® 61 Trofex 61 Phase IIb clinical 61 ribavirin RBV 61 PEG PAL 61 subcutaneous formulation 61 idarubicin 61 peginterferon 61 plus gemcitabine 61 Doxil ® 61 CBLC# 61 etanercept 61 Folotyn 61 oral FTY# 61 CorVue ™ 61 PEG IFN 61 IAP inhibitor 61 systemically administered 61 peg interferon 61 oral rivaroxaban 61 eprotirome 61 Reolysin 61 nucleoside analog 61 INCB# [003] 61 HCV SPRINT 61 IRX 2 61 Herceptin trastuzumab 61 REMINYL ® 61 subcutaneously administered 61 anti EGFR antibody 61 Cimzia TM 61 Natalizumab 61 sipuleucel T 61 tamibarotene 61 alefacept 61 AZILECT ® 61 Cethrin 61 MACUGEN 61 omega interferon 61 bortezomib Velcade ® 61 bortezomib Velcade 61 PRTX 61 dasatinib Sprycel ® 61 refractory AML 61 Neurodex 61 trastuzumab Herceptin R 61 candesartan cilexetil 61 pharmacodynamic profile 61 febuxostat 61 orally bioavailable 61 AMEVIVE 61 Phase 1a 61 tipranavir 61 Peg IFN 61 rosuvastatin #mg 61 antibody MAb 61 dose cohort 61 CCX# 61 anti leukemic 60 cancer mCRC 60 Aptivus 60 bifeprunox 60 protein kinase inhibitor 60 TMC# [001] 60 Corlux 60 ORENCIA R 60 IFN α 60 plus Copegus R 60 pharmacodynamic effects 60 Stedivaze 60 Phase IIIb clinical 60 SEROQUEL XR 60 Fx #A 60 viral kinetics 60 CYCLOSET 60 Gabapentin GR 60 DEB# 60 rHuPH# 60 MAXY G# 60 efalizumab 60 Tavocept 60 selective androgen receptor modulator 60 bevacizumab 60 Ranibizumab 60 TRO# 60 ZYBRESTAT fosbretabulin 60 Aptivus ® 60 Irinotecan 60 Androxal TM 60 lesinurad 60 recurrent NSCLC 60 ZYVOX 60 pegylated interferons 60 prospectively defined 60 Lenalidomide 60 TTF Therapy 60 radiation sensitizer 60 MERLIN TIMI 60 5-FU/LV 60 Pazopanib 60 Denufosol 60 Leukine ® 60 phase IIb study 60 follicular NHL 60 Viramidine 60 lixisenatide 60 multi kinase inhibitor 60 docetaxel Taxotere 60 BNC# 60 Initiate Phase 60 Parkinson disease levodopa induced 60 reslizumab 60 diabetic neuropathic pain 60 dasatinib 60 vascular disrupting agent 60 bafetinib 60 Clevudine 60 picoplatin 60 Aplidin R 60 palonosetron 60 AVE# 60 Mylotarg 60 paclitaxel poliglumex 60 ENBREL 60 erlotinib Tarceva 60 PLK1 SNALP 60 thalidomide Thalomid 60 pramlintide 60 TMC# [002] 60 Civacir 60 sunitinib Sutent 60 Sapacitabine 60 refractory CLL 60 peginterferon alfa 60 multiple ascending dose 60 Xelox 60 dose escalation Phase 60 Phase #b/#a trial 60 administered subcutaneously 60 XL# XL# XL# 60 huN# DM1 60 CD3 monoclonal antibody 60 IRESSA 60 Enzastaurin 60 teplizumab 60 tivozanib 60 mycophenolate mofetil 60 Panitumumab 60 Safinamide 60 Hepatocellular Carcinoma HCC 60 brentuximab vedotin 60 SEROQUEL 60 integrase inhibitor 60 darapladib 60 cabazitaxel 60 EVIZON 60 ascending doses 60 indacaterol 60 Bicifadine 60 oral anticoagulant 60 multiple myeloma MM 60 Ophena TM 60 boosted protease inhibitor 60 elesclomol 60 rufinamide 60 liposomal formulation 60 p# biomarker 60 Xeloda ® 60 tafamidis 60 goserelin 60 Temsirolimus 60 blinded randomized placebo controlled 60 intravitreal injection 60 dose escalation 60 hormone refractory prostate cancer 60 Phase IIa trials 60 SYMBICORT 60 relapsed MM 60 lapatinib 60 ThermoDox R 60 somatostatin analogue 60 Seliciclib 60 COMFORT II 60 regorafenib 60 Phase 2b 60 pazopanib 60 DOXIL 60 G CSF 60 IMC #B 60 oral deforolimus 60 PLX# 60 relapsing remitting multiple sclerosis 60 TASQ 60 GLPG# 60 PEGylated interferon beta 1a 60 opioid induced bowel dysfunction 60 placebo controlled randomized 60 Desmoteplase 60 metreleptin 60 lumiliximab 60 interferon therapy 60 INC# 60 EDEMA3 60 Octreolin 60 ONGLYZA ™ 60 ADVANCE PD 60 fluvastatin 60 pivotal Phase III 60 Pivotal Phase 60 ascending dose 60 MBP# [001] 60 octreotide 60 6R BH4 60 BMS# 60 pegylated interferon alpha 60 refractory CTCL 60 Adlea 60 elagolix 60 maraviroc 60 5 fluorouracil leucovorin 60 ATL# [001] 60 xanthine oxidase inhibitor 60 refractory multiple myeloma 60 OMNARIS HFA 60 RGB # 60 XGEVA 60 eculizumab 60 Pemetrexed 60 Curaxin CBLC# 60 OHR/AVR# 60 leukemia CLL 60 linaclotide 60 albiglutide 60 COPEGUS 60 Phase IIb 60 afatinib 60 PNP inhibitor 60 NXL# 60 icatibant 60 small molecule Hedgehog 60 leukemia AML 60 Carfilzomib 60 histone deacetylase inhibitor 60 Romidepsin 60 Myocet 60 Phase #/#a trial 60 Darusentan 60 Interferon beta 1a 60 SPRYCEL ® 60 aleglitazar 60 palifosfamide 60 Xcellerated T Cells 60 ILLUMINATE 60 Atrasentan 60 proteasome inhibitor 60 Vidaza azacitidine 60 pegylated interferon alpha 2a 60 varespladib 60 PKC# 60 Rebif ® 60 Omnitarg 60 trastuzumab Herceptin 60 lubiprostone 60 sodium glucose cotransporter 60 Alzhemed TM 60 Omacetaxine 60 tolerability 60 AQ4N 60 Cloretazine ® 60 cannabinor 60 fluoropyrimidine 60 cetuximab 60 orally administered inhibitor 60 liposomal doxorubicin 60 myelofibrosis MF 60 deforolimus 60 Selzentry 60 eszopiclone 60 CIMZIA TM certolizumab pegol 60 weekly subcutaneous injections 60 Meets Primary Endpoint 60 APOPTONE 60 MNTX 60 Clolar 60 LEUKINE 60 Annamycin 60 Promacta 60 abiraterone 60 alkylating agent 59 INTELENCE 59 cangrelor 59 satraplatin 59 Phase III clinical 59 CD# monoclonal antibody 59 VA# [002] 59 dosing cohort 59 ocular hypertension 59 tipranavir r 59 farletuzumab 59 Elvitegravir 59 voreloxin 59 Phase 2b clinical trials 59 abiraterone acetate 59 mCRC patients 59 elacytarabine 59 investigational protease inhibitor 59 FOLFOX 59 laquinimod 59 tarenflurbil 59 OvaRex ® MAb 59 alemtuzumab Campath 59 DACH platinum 59 QAB# 59 Alfimeprase 59 desvenlafaxine succinate 59 Voreloxin 59 Pivotal Phase III 59 Phase IIb clinical trials 59 GTC recombinant human 59 rFVIIa 59 mGluR5 negative 59 Telcyta 59 Fludara ® 59 Daclizumab 59 volociximab 59 PEGINTRON 59 sitagliptin 59 Telaprevir 59 GAMMAGARD LIQUID 59 gemcitabine Gemzar ® 59 confirmatory Phase III 59 anakinra 59 Preclinical studies suggest 59 gemcitabine carboplatin 59 CRx 59 CLORETAZINE TM VNP#M 59 randomized controlled Phase 59 Jevtana 59 ATryn ® 59 ADP receptor antagonist 59 MAP# 59 pegaptanib 59 relapsing remitting MS RRMS 59 Boceprevir 59 pediatric malignancies 59 antitumor activity 59 Ceplene 59 Rasagiline 59 Omacetaxine mepesuccinate 59 cisplatin vinorelbine 59 pharmacokinetic profiles 59 Alemtuzumab 59 TRISENOX 59 metastatic castration resistant 59 rosuvastatin 59 JANUVIA 59 novel histone deacetylase 59 neurologic progression 59 protease inhibitor 59 abatacept Orencia 59 fulvestrant 59 Plenaxis TM 59 Zelrix 59 induced macular edema 59 tasimelteon 59 CTCE 59 RhuDex ® 59 plus ribavirin 59 Microplasmin 59 anti angiogenic agent 59 prucalopride 59 Alocrest 59 Sprycel dasatinib 59 cutaneous T 59 orally dosed 59 INT# [002] 59 ocular formulation 59 relapsed SCLC 59 dasatinib Sprycel 59 ranibizumab Lucentis 59 pegylated interferon alfa 2b 59 ENMD # 59 CYC# 59 colesevelam HCl 59 pan HDAC inhibitor 59 Hycamtin 59 partial agonist 59 insulin detemir 59 MIRCERA 59 mcg dose 59 IIa trial 59 refractory gout 59 topotecan 59 TNF inhibitor 59 gastrointestinal stromal tumor GIST 59 AzaSite Plus 59 pegfilgrastim 59 vilazodone 59 ularitide 59 lacosamide 59 aflibercept VEGF Trap 59 pain palliation 59 Allovectin 7 ® 59 danoprevir 59 STRIDE PD 59 IV NSCLC 59 citalopram 59 Cimzia R 59 PSMA ADC 59 ARIKACE 59 Romiplostim 59 Firazyr 59 pharmacokinetics PK 59 B CLL 59 ataluren 59 Guanilib 59 Taxotere R 59 Alpharadin 59 non nucleoside 59 agomelatine 59 VPRIV 59 Ceflatonin ® 59 Gattex 59 BRAF V#E mutation 59 CHOP chemotherapy 59 Zenvia Phase III 59 Exelixis compounds 59 pharmacodynamics PD 59 ImClone Erbitux 59 maximally tolerated dose 59 Dual Opioid 59 aliskiren 59 RSD# oral 59 Ceflatonin R 59 stage IIIB 59 safety tolerability pharmacokinetic 59 leucovorin 59 exenatide 59 tolerability profile 59 PEGylated anti 59 PI3K inhibitor 59 Sorafenib 59 FAMPYRA 59 RAPTIVA 59 Canvaxin 59 JAK1 59 Teriflunomide 59 pegylated interferon 59 TH# [003] 59 idraparinux 59 Actemra tocilizumab 59 donepezil Aricept 59 investigational drug 59 TOLAMBA 59 Cimzia ® 59 NOXAFIL 59 estramustine 59 CTAP# Capsules 59 DAVANAT R 59 ARCALYST 59 anticancer therapy 59 severe hypercholesterolemia 59 CCR5 antagonist 59 Milnacipran 59 ILUVIEN ® 59 orBec 59 PEG interferon 59 REBETOL combination therapy 59 atrasentan 59 PDX pralatrexate 59 oral methylnaltrexone 59 Xinlay 59 Telintra 59 PHX# 59 TriRima 59 Increlex R 59 #D#C# 59 LHON 59 bicalutamide 59 Ixabepilone 59 Yondelis ® 59 non squamous NSCLC 59 tolvaptan 59 GV# [001] 59 rALLy clinical trial 59 Nuvion 59 ANAVEX #-# [001] 59 Durezol 59 COPAXONE R 59 mg BID 59 paclitaxel Taxol ® 59 Icatibant 59 dose escalation clinical 59 PrevOnco 59 REYATAZ R 59 terlipressin 59 dosage regimens 59 hormone LHRH antagonist 59 torezolid phosphate 59 Peginterferon alfa 2b 59 inhaled iloprost 59 peginterferon alfa 2a Pegasys 59 Treanda 59 IMiDs 59 capecitabine Xeloda R 59 MEK inhibitors 59 opioid induced constipation OIC 59 capecitabine 59 interferon alfa 2b 59 Starlix 59 PRE SURGE 59 nucleotide analog 59 chronic HCV infection 59 rotigotine 59 Aurexis 59 lomitapide 59 nonclinical studies 59 phase 2a 59 rasagiline 59 Onconase